Paediatric biopharmaceutics classification system: current status and future decisions

Hannah Batchelor*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

Biopharmaceutical methods are routinely used in the design of medicines to predict in vivo absorption and hence guide the development of new products. Differences in anatomy and physiology of paediatric patients require adaptation of existing biopharmaceutical methods to ensure that in vivo predictions are relevant for this population. The biopharmaceutics classification system is a tool used in drug development to guide formulation selection and manufacture from early clinical studies through to product launch. The applicability of the biopharmaceutics system to paediatric product development has yet to be explored; this note brings together some key issues in direct extrapolation from adults into paediatric populations.

Original languageEnglish
Pages (from-to)251-253
Number of pages3
JournalInternational Journal of Pharmaceutics
Volume469
Issue number2
DOIs
Publication statusPublished - 5 Aug 2014

Keywords

  • biopharmaceutics
  • dose number
  • paediatric
  • solubility

Fingerprint

Dive into the research topics of 'Paediatric biopharmaceutics classification system: current status and future decisions'. Together they form a unique fingerprint.

Cite this